Clinical AdvancementsBoth drug candidates have exhibited well-tolerated safety profiles, favorable functional improvements, and positive clinical outcomes, and are poised to advance toward late-stage development.
Financial PerformanceEdgewise announced financial results with EPS better than both the company's and consensus estimates.
Regulatory ApprovalSevasemten aims to become the first approved drug for Becker muscular dystrophy and an adjuvant for Duchenne muscular dystrophy standard of care.